Abiraterone acetate versus bicalutamide in combination with gonadotropin releasing hormone antagonist therapy for high risk metastatic hormone sensitive prostate cancer

Abstract The objective of this study was to compare the efficacy of abiraterone acetate with that of bicalutamide in combination with gonadotropin-releasing hormone (GnRH) antagonist treatment for patients with high-risk metastatic hormone-sensitive prostate cancer (mHSPC). A total of 149 patients w...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Takashi Ueda, Takumi Shiraishi, Saya Ito, Munehiro Ohashi, Toru Matsugasumi, Yasuhiro Yamada, Atsuko Fujihara, Fumiya Hongo, Koji Okihara, Osamu Ukimura
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
R
Q
Acceso en línea:https://doaj.org/article/b60f435352f8409780bd19222a2b875c
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!